Background Most studies analyzing prognostic factors for late relapse have been performed in postmenopausal women who received tamoxifen or aromatase inhibitors as adjuvant endocrine therapy for estrogen receptor (ER)-positive breast cancer. Methods A total of 223 patients (108 premenopausal and 115 postmenopausal) with early distant recurrence and 149 patients (62 premenopausal and 87 postmenopausal) with late distant recurrence of ER-positive, HER2-negative breast cancer who were given their initial treatment between 2000 and 2004 were registered from nine institutions. For each late recurrence patient, approximately two matched control patients without relapse for more than 10 years were selected. Clinicopathological factors and adjuvant therapies were compared among the three groups by menopausal status and age.
Results Factors predicting early recurrence in premenopausal women were large tumor size, high lymph node category and high tumor grade, whereas predictors for late recurrence were large tumor size and high lymph node category. In postmenopausal women under 60 years of age, factors predicting early recurrence were bilateral breast cancer, large tumor size, high lymph node category, low PgR expression and high Ki67 labeling index (LI), while predictors for late recurrence were large tumor size and high lymph node category. On the other hand, in postmenopausal women aged 60 years or older, factors predicting early recurrence were bilateral breast cancer, large tumor size, high lymph node category, high tumor grade, low ER expression and high Ki67 LI, whereas predictors for late recurrence were high lymph node category, low ER expression and short duration of adjuvant endocrine therapy.
Introduction
Adjuvant therapies for early breast cancer have had a substantial beneficial effect on disease outcome [1] [2] [3] . Adjuvant chemotherapy has proven to be effective in reducing the risk of recurrence within the first 5 years after diagnosis [3] . However, women with estrogen receptor (ER)-positive breast cancer remain at particular risk of late recurrence which is defined as relapse more than 5 years after initial treatment [4] . Recent studies demonstrated that extended adjuvant endocrine therapy reduces late recurrence [5, 6] . Therefore, accurate and reliable estimates of the risk of recurrence after 5 years of endocrine therapy are necessary to enable appropriate decisions regarding extended endocrine therapy. It has been considered that the risk of long-term relapse is related to the number of positive lymph nodes and large size of invasive tumors [7] . Furthermore, multi-parameter molecular assays, including IHC4, OncotypeDX, EndoPredict, PAM50 and Breast Cancer Index, have been developed for predicting early and/or late distant recurrence [7, 8] .
In addition to tumor biology, host factors, such as menopausal status, age or body mass index, and adjuvant therapies may influence disease prognosis [9] . Moreover, host factors may influence tumor biology. To date, most studies analyzing prognostic factors for early and late relapse have been performed in postmenopausal women, mainly using patients and samples in adjuvant aromatase inhibitor trials [10] [11] [12] [13] , in which patients received tamoxifen or aromatase inhibitors as adjuvant endocrine therapy. Kennecke and colleagues retrospectively analyzed risk of early [14] and late recurrence [15] among postmenopausal women with ER-positive early breast cancer treated with adjuvant tamoxifen. However, prognostic factors for especially late relapse might differ between patients who received adjuvant tamoxifen and those who were treated with aromatase inhibitors. Furthermore, there are few studies on prognostic factors for early and late recurrence in premenopausal ER-positive breast cancer.
The present study was a multi-institutional joint study carried out as Scientific Research of the Japanese Breast Cancer Society. We retrospectively collected data from ER-positive, HER2-negative breast cancer patients with early and late distant relapse and patients who remained relapse free for more than 10 years. All patients were given their initial treatment between 2000 and 2004. Clinicopathological factors and adjuvant therapies were compared among patients with early and late distant recurrence and patients without recurrence by menopausal status and age.
Patients and methods

Patients and breast cancer samples
A total of 223 consecutive patients with early distant recurrence and 149 consecutive patients with late distant recurrence of ER-positive, HER2-negative breast cancer who had undergone breast surgery or neoadjuvant chemotherapy between January 2000 and December 2004 were registered from nine institutions, joining a multi-institutional joint study titled 'Analysis on biological characteristics and factors predicting late recurrence in breast cancer', carried out as Scientific Research of the Japanese Breast Cancer Society. Early recurrence was defined as relapse within 5 years, and late recurrence was defined as relapse more than 5 years after initial treatment. For each late recurrence patient, approximately two age-matched control patients without relapse for more than 10 years were randomly selected using RAND in combination with Excel software at each institution. Clinicopathological factors and adjuvant therapies were compared among the three groups. The study protocol was approved by the institutional review board and conformed to the guidelines of the 1996 Declaration of Helsinki in all nine institutions.
Immunohistochemical evaluation of ER, PgR, HER2 and Ki67 expression
Expression of ER, progesterone receptor (PgR), HER2 and Ki67 was centrally assessed by immunohistochemistry (IHC). Primary antibodies included monoclonal mouse anti-human ERa antibody (1D5, DAKO, Glostrup, Denmark) at 1:100 dilution, monoclonal mouse anti-human PgR antibody (636, DAKO) at 1:100 dilution and monoclonal mouse anti-human Ki67 antibody (MIB-1, DAKO) at 1:200 dilution. ER was considered positive if there was C1 % positive nuclear staining. The Ki67 labeling index (LI) was assessed as the percentage of tumor cells showing definite nuclear staining among [1000 invasive tumor cells. Immunostaining of HER2 was evaluated using the HercepTest (DAKO). Tumors with a score of 2? were tested for gene amplification by in situ hybridization (ISH). Tumors were considered HER2 positive if IHC staining was 3? or ISH positive. HER2-positive tumors were excluded from this study.
Statistical analysis
The Chi-squared test and Student's t test were used to compare clinicopathological characteristics and treatments among patients with early and late recurrence and without recurrence. The differences between expression levels of ER and PgR, and Ki67 LI corresponding to menopausal status and age were compared by one-way ANOVA followed by Scheffe's test.
Results
We collected data from a total of 223 women (108 premenopausal and 115 postmenopausal) with early distant recurrence, 149 women (62 premenopausal and 87 postmenopausal) with late distant recurrence and 321 women (150 premenopausal and 171 postmenopausal) without relapse for more than 10 years with ER-positive, HER2-negative breast cancer.
Prognostic factors for early and late distant recurrence in premenopausal women
Premenopausal women with both early and late recurrence had larger clinical tumor size (p \ 0.0001 and p \ 0.0001, respectively) and higher clinical lymph node category (p \ 0.0001 and p \ 0.0001, respectively) than those without recurrence (Table 1) . Tumor grade (p = 0.0079) was significantly higher in patients with early recurrence, but not in patients with late recurrence (p = 0.18), compared with those without recurrence. On the other hand, expression levels of ER and PgR, and Ki67 LI did not differ between premenopausal women with early and late recurrence and those without recurrence (Table 1) .
Adjuvant treatment in premenopausal women
Among women with distant recurrent tumors, 64.8 % with early recurrence and 66.1 % with late recurrence received both endocrine therapy and chemotherapy, while among patients without recurrence, 50.0 % received endocrine therapy alone and 36.0 % received both endocrine therapy and chemotherapy (p \ 0.0001 and p = 0.007, respectively, Table 2 ). Among patients with early recurrence who received adjuvant or neoadjuvant chemotherapy, 26.9 % received anthracyclines and 36.1 % received both anthracyclines and taxanes. Similarly, 25.8 % of women with late recurrence received anthracyclines and 35.5 % received both anthracyclines and taxanes. In contrast, among patients without recurrence, 12.0 % of women received anthracyclines and 16.7 % received both anthracyclines and taxanes. Thus, more of the patients with early and late distant recurrence had received adjuvant or neoadjuvant chemotherapies, including anthracyclines and/or taxanes. Among patients who had received neoadjuvant chemotherapy, no tumors in patients with early or late recurrence achieved pathological complete response (pCR), whereas one patient without recurrence achieved pCR ( Table 2 ).
Prognostic factors for early and late distant recurrence in postmenopausal women
Postmenopausal women with early and late recurrence had significantly more incidences of bilateral breast cancer (p = 0.0001 and p \ 0.0001, respectively), larger tumor size (p \ 0.0001 and p = 0.0097, respectively) and higher lymph node category (p \ 0.0001 and p = 0.0006, respectively) than those of control patients (Table 3) . Tumor grade (p = 0.001) and Ki67 LI (p = 0.0006) were significantly higher, and expression levels of PgR (p = 0.005) were significantly lower in patients with early recurrence, but not in patients with late recurrence, compared with controls (Table 3) .
Adjuvant treatment in postmenopausal women
Of the patients with distant recurrence, 42.6 % of women with early recurrence and 34.5 % of women with late recurrence received both endocrine therapy and chemotherapy, whereas in patients without recurrence 64.9 % received endocrine therapy alone and 25.1 % received both endocrine therapy and chemotherapy (p \ 0.0001 and p = 0.033, respectively, Table 4 ). Among patients with early recurrence who received adjuvant or neoadjuvant chemotherapy, 12.2 % received anthracyclines and 37.4 % received both anthracyclines and taxanes, whereas in patients with late recurrence 20.7 % of women received anthracyclines and 14.9 % received both anthracyclines and taxanes. In contrast, among patients without recurrence, 12.9 % received anthracyclines and 9.9 % received both anthracyclines and taxanes. Thus, similar to the findings in premenopausal women, more of the patients with early recurrence had received adjuvant or neoadjuvant chemotherapies, including anthracyclines and/or taxanes. Difference between two age groups (<60 and ‡60 years) in postmenopausal women in terms of predicting early and late distant recurrence
Anderson and colleagues demonstrated the existence of earlyonset (progressing before menopause) and late-onset (progressing after menopause) breast cancers [16] , and we suggest that the mechanisms of development and estrogen-dependent growth of ER-positive breast cancer might differ according to menopausal status [17, 18] . Although most cases of ER-positive breast cancer in postmenopausal women aged 60 years or older are likely to be late-onset, both early-onset and lateonset breast cancers are included in postmenopausal breast cancer diagnosed under 60 years of age. Therefore, we next analyzed postmenopausal patients in the two age groups (\60 and C60 years) separately. In both age groups, women with early recurrence had significantly more incidences of bilateral breast cancer (p = 0.0087 and p = 0.0035, respectively), larger tumor size (p = 0.0009 and p \ 0.0001, respectively), higher clinical lymph node category (p \ 0.0001 and p \ 0.0001, respectively) and higher Ki67 LI (p = 0.039 and p = 0.0077, respectively) compared with women without recurrence (Tables 5, 6 ). On the other hand, PgR expression was significantly lower (p = 0.019, Table 5 ) in patients with early recurrence under 60 years of age, but not in patients aged 60 years or older (Table 6 ), compared with controls. Tumor grade was significantly higher (p = 0.0017, Table 6 ) and expression levels of ER were significantly lower (p = 0.0037, Table 6 ) in patients with early recurrence aged 60 years or older, but not in patients under 60 years of age (Table 5) , compared with controls.
In patients with late recurrence, women in both age groups had significantly higher lymph node category (p = 0.023 and p = 0.0062, respectively) compared with women without recurrence (Tables 5, 6 ). However, although tumor size was significantly larger (p = 0.015, Table 5 ) in patients under 60 years of age, it was not in patients aged 60 years or older (p = 0.10, Table 6 ), compared with controls. ER expression was significantly lower (p = 0.0025, Table 6 ) in patients aged 60 years or older, but not in patients under 60 years of age (p = 0.20, Table 5 ), compared with controls. There were fewer patients with late recurrence among those who had received adjuvant aromatase inhibitors for more than 2, 3 or 4 years in the group of postmenopausal women aged 60 years or older (p = 0.042, p = 0.0095, and p = 0.0003, respectively, Table 6 ), but not in postmenopausal women under 60 years of age (Table 5) .
Expression levels of ER and PgR, and Ki67 LI in patients without recurrence by menopausal status and age
We compared expression levels of ER and PgR and Ki67 LI in patients without recurrence among 4 groups defined by menopausal status and age (Fig. 1) . ER expression was significantly higher in postmenopausal women compared with that in premenopausal women, although there was no difference between the two age groups of each menopausal status (\40 years and C40 years in premenopausal women and \60 and C60 years in postmenopausal women, Fig. 1a) . In contrast, PgR expression was significantly higher in premenopausal women compared with that in postmenopausal women (Fig. 1b) . Ki67 LI in postmenopausal women aged 60 years or older was significantly lower than that in premenopausal women under 40 years of age (p = 0.006, Fig. 1c ). Mean Ki67 LI was 9.1 % in postmenopausal women aged 60 years or older and 19.7 % in premenopausal women under 40 years of age. These results suggested that clinical roles or cutoffs of PgR and Ki67 in ER-positive breast cancer might differ between pre-and postmenopausal women.
Discussion
We investigated clinicopathological factors and adjuvant therapies predicting early and late distant recurrence in ERpositive, HER2-negative breast cancer by menopausal status and age. Our results demonstrated that factors predicting early recurrence in premenopausal women were large tumor size, high lymph node category and high tumor grade, whereas predictors for late recurrence in premenopausal women were large tumor size and high lymph node category. In postmenopausal women under 60 years of age, factors predicting early recurrence were bilateral breast cancer, large tumor size, high lymph node category, low PgR expression and high Ki67 LI, while predictors for late recurrence were large tumor size and high lymph node category. On the other hand, in postmenopausal women aged 60 years or older, factors predicting early recurrence were bilateral breast cancer, large tumor size, high lymph node category, high tumor grade, low ER expression and high Ki67 LI, whereas predictors for late recurrence were high lymph node category, low ER expression and short duration of adjuvant endocrine therapy (especially, aromatase inhibitors).
To date, most studies analyzing predictive or prognostic factors in ER-positive breast cancer have been performed in postmenopausal women, mainly using patients and samples in adjuvant aromatase inhibitor trials [8] . In contrast, even the clinical roles of PgR and Ki67 have been little analyzed so far in premenopausal women, although testing of PgR and Ki67 by IHC has become routine [19, 20] . Recent studies indicated that plasma estradiol levels are related to expression levels of estrogen-responsive genes, including PgR, in ER-positive breast cancer tissues in both pre-and postmenopausal women [21, 22] . We previously analyzed expression levels of estrogen-responsive genes and Ki67 in ER-positive, HER2-negative breast cancer, and suggested that clinical roles of PgR and Ki67 might differ between pre-and postmenopausal women [17] . In this study, we demonstrate that expression levels of ER and PgR, and Ki67 LI in patients without recurrence differ between pre-and postmenopausal women. It was recently reported that comparing ER-positive pre-and postmenopausal breast cancer by analyzing gene expression, copy number, methylation, somatic mutation and reverse-phase protein array data using TCGA and METABRIC databases revealed that ER-positive premenopausal tumors have distinct molecular characteristics compared to ER-positive postmenopausal tumors, particularly with respect to integrin/laminin and EGFR signaling [23] . We previously analyzed genetic and environmental factors, endogenous hormones and growth factors to identify risk factors for ER-positive breast cancer, and showed that risk factors differ between women of different menopausal status [18] . It has been demonstrated that there are bimodal pre-and postmenopausal breast cancer populations divided by Clemmesen's menopausal hook, and the etiology of pre-and postmenopausal breast cancer is, TAM tamoxifen, LHRH agonist luteinizing hormone-releasing hormone agonist, AI aromatase inhibitor, Anthracyclines AC (doxorubicin and cyclophosphamide), EC epirubicin and cyclophosphamide) or FEC (fluorouracil, epirubicin and cyclophosphamide), Taxanes docetaxel or paclitaxel, CMF cyclophosphamide, methotrexate and fluorouracil, CR complete response, PR partial response, SD stable disease, PD progressive disease * p \ 0.05 is considered significant 60 years or older. Specifically, patients with both early and late recurrence had significantly lower ER expression compared with controls in postmenopausal women aged 60 years or older, but not in women under 60 years of age. This suggests that most ER-positive breast cancer might be late-onset in postmenopausal women aged 60 years or older. In contrast, both early-onset and late-onset breast cancers are included in postmenopausal breast cancer diagnosed under 60 years of age [16] . Thus, a biological difference between the two age groups (\60 and C60 years) might become apparent in postmenopausal ERpositive breast cancer. Previous studies reported that tumor grade and Ki67 expression were predictive only of recurrence in the first 5 years after diagnosis [7, 12] . The present study also indicated that tumor grade and/or Ki67 LI were predictors of early recurrence, but not of late recurrence in both preand postmenopausal women. Furthermore, more of the patients with early recurrence had received adjuvant or neoadjuvant chemotherapies, including anthracyclines and/ or taxanes in our analysis. This may not be surprising because patients with early recurrence had larger tumor size, higher lymph node category and higher tumor grade or higher Ki67 LI compared with patients without recurrence. Approximately two-thirds of both pre-and postmenopausal patients who relapsed within 5 years had received anthracyclines and/or taxanes as adjuvant or neoadjuvant chemotherapy. Thus, these standard chemotherapies might not be enough for prevention of early relapse in many patients regardless of high tumor grade or high Ki67 LI. Standard adjuvant chemotherapy regimens should be reconsidered, especially for ER-positive, HER2-negative breast cancer.
This study has some limitations; it is a retrospective study without validation, and approximately two age-matched control patients without relapse were randomly selected for each late recurrence patient. However, almost 80 % of postmenopausal women received aromatase inhibitors as adjuvant endocrine therapy, and the duration of adjuvant aromatase inhibitor therapy was a predictive factor for late recurrence in postmenopausal women aged 60 years or older. Furthermore, anthracyclines and/or taxanes were used as adjuvant chemotherapy, because patients in our analysis had undergone initial treatments between 2000 and 2004.
In conclusion, our study demonstrates that predictors of early and late distant recurrence differ between patients of different menopausal status, and between those postmenopausal women under 60 years of age and those aged 60 years or older. Menopausal status and age as well as tumor biology should be taken into account when planning the care of ER-positive, HER2-negative breast cancer.
